NexEos Diagnostics, Inc
Wayne, PA · Founded 2019 · CIK 0001783828 · Medtech · Private
Non-invasive molecular imaging agent for eosinophilic esophagitis diagnosis and monitoring
nexeosdx.com →- Grants
- $891K
- 3 awards
- Sector median: 1
- Raised
- $26M
- 5 Form D · Feb 2026
- 8 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 1 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $3,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel, Non-InvasiveImaging of Eosinophil-Related Inflammation Throughout the Esophagus in Patients withEosinophilic Esophagitis | $299,982 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Treatment for Eosinophil-Mediated Allergic Inflammatory Diseases Utilizing a Neutralizing Agent Targeting Eosinophil Granule Major Basic Protein | $299,846 | |
| Private capital raised | Form D · SEC | $9,677,639 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Treatment for Eosinophil-Mediated Allergic Inflammatory Diseases Utilizing a Neutralizing Agent Targeting Eosinophil Granule Major Basic Protein | $290,732 | |
| Private capital raised | Form D · SEC | $5,100,000 | |
| Private capital raised | Form D · SEC | $4,916,907 | |
| Private capital raised | Form D · SEC | $3,000,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1197 | PathSpot Technologies, Inc. | — | $3.7M |
| 1198 | PROTEOWISE, INC. | — | $11M |
| 1199 | Pathr.ai, Inc. | — | $7.3M |
| 1200 | NexEos Diagnostics, Inc | — | $26M |
| 1201 | AXON MEDICAL, INC. | — | — |
| 1202 | AVSANA LABS INCORPORATED | — | — |
| 1203 | Boundless Devices, Inc. | — | $2.8M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Jeff HimawanDirector
- Jeffrey HimawanDirector
- Dennis LangerDirector
- Theresa MansiDirector · Executive Officer
- Louis ManziDirector
- Christopher MolineauxDirector
- Nicholas SicilanoDirector
- Nicholas SicilianoDirector
- Stephen TullmanDirector · Executive Officer
Patents
- Acidic Polymer Compositions And Methods Of Use Thereofapplication
- Methods Of Manufacturing A High Molecular Weight Heparin Compoundapplication
- Methods Of Manufacturing A High Molecular Weight Heparin Compoundgranted
- Acidic Polymer Compositions And Methods Of Use Thereofapplication
- Acidic Polymer Compositions And Methods Of Use Thereofapplication
- Methods Of Manufacturing A High Molecular Weight Heparin Compoundapplication
- Methods Of Manufacturing A High Molecular Weight Heparin Compoundapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.